TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech ...

TD Cowen analyst Dan Brennan reinstated coverage of Tempus AI (TEM) with a Buy rating and price target of $74, up from $58, following the ...

TD Cowen reaffirmed their buy rating on shares of Tempus AI (NASDAQ:TEM – Free Report) in a research note published on Wednesday, Marketbeat Ratings reports. TD Cowen currently has a $74.00 price ...

TD Cowen reinitiated coverage on Tempus AI Inc (NASDAQ:TEM) with a Buy rating, increasing the price target to $74 from a previous target. The stock, currently trading at $61.85, has shown remarkable ...

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free ...

Up about 12%, Tempus AI (NASDAQ:TEM) has been explosive. Helping, its volume just spiked to 18.6 million shares, as compared ...

Multiple executives at Tempus AI Inc. executed significant share sales totaling $20.3 million between Feb. 4-7, according to ...

The stock market extended its winning streak on Wednesday, closing firmer as investors seemed to have already priced in the ...

The bank had suspended its rating and price target for Tempus during its $600 million acquisition of Ambry Genetics due to TD Securities' involvement in the deal.

In a regulatory filing, Tempus AI (TEM) disclosed that COO Ryan Fukushima sold 20,000 shares of the company’s stock. The stock was sold at an ...